Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds
Prices tend to be set below the reimbursement system's thresholds and these appear to be ceilings, but decision makers should anticipate that drug companies will adjust prices in response to reimbursement policy, at least to some degree.
Authors
- Martin Henriksson (ORCID: https://orcid.org/0000-0003-1699-3185)
- Jonathan Siverskog (ORCID: https://orcid.org/0000-0003-4853-5576)
- Anton P H Klockhoff
Institutions
- Linköping University (SE)
Publication Details
- Journal
- Value in Health
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1016/j.jval.2025.07.027
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vetenskapsrådet